Balance Sheet
Accounts PayablesAssetsCapital LeasesCash & Current InvestmentsCash & EquivalentsCommon EquityCurrent AssetsCurrent Deferred RevenueCurrent LeasesGoodwillGoodwill & IntangiblesIntangiblesInventoryLiabilities and Shareholders EquityLong-Term Deferred TaxMinority InterestNon-Current AssetsNon-Current DebtOperating LeasesOther Accumulated ExpensesOther Non-Current AssetsOther Non-Current LiabilitiesPayablesPreferred SharesPrepaid AssetsProperty, Plant & Equipment (Net)Property, Plant & Equipment (Net)ReceivablesReceivables - NetReceivables - OtherRetained EarningsShareholder's EquityShares OutstandingShort term DebtTotal Current LiabilitiesTotal DebtTotal LiabilitiesTotal Non-Current LiabilitiesTreasury SharesTreasury Shares
Cash Flow Statement
Daily Values
Growth Metrics
Income Statement
Others
Ratios

AdaptHealth (AHCO) Minority Interest (2018 - 2026)

AdaptHealth has reported Minority Interest over the past 8 years, most recently at $7.8 million for Q4 2025.

  • For Q4 2025, Minority Interest rose 11.32% year-over-year to $7.8 million; the TTM value through Dec 2025 reached $7.8 million, up 11.32%, while the annual FY2025 figure was $7.8 million, 11.32% up from the prior year.
  • Minority Interest for Q4 2025 was $7.8 million at AdaptHealth, down from $8.1 million in the prior quarter.
  • Over five years, Minority Interest peaked at $9.2 million in Q1 2024 and troughed at $4.1 million in Q2 2021.
  • A 5-year average of $6.4 million and a median of $6.6 million in 2022 define the central range for Minority Interest.
  • Biggest five-year swings in Minority Interest: skyrocketed 109.58% in 2021 and later crashed 34.47% in 2025.
  • Year by year, Minority Interest stood at $4.8 million in 2021, then soared by 37.99% to $6.6 million in 2022, then rose by 24.47% to $8.2 million in 2023, then dropped by 15.12% to $7.0 million in 2024, then rose by 11.32% to $7.8 million in 2025.
  • Business Quant data shows Minority Interest for AHCO at $7.8 million in Q4 2025, $8.1 million in Q3 2025, and $6.7 million in Q2 2025.